Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat

Liver International

Volumn 30, Issue 7, 2010, Pages 969-978

  Chávez, Enrique ^a   Segovia, José ^a   Shibayama, Mineko ^a   Tsutsumi, Victor ^a   Vergara, Paula ^a   Castro Sánchez, Luis ^a   Salazar, Eduardo Pérez ^a   Moreno, Mario G ^a   Muriel, Pablo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Antifibrogenic; Celecoxib; Cyclooxygenase; Fibrolytic; Fibrosis; Metalloproteinase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CARBON TETRACHLORIDE; CELECOXIB; COLLAGEN; CYCLOOXYGENASE 2; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; GLUTATHIONE; GLYCOGEN; MINERAL OIL; PROSTAGLANDIN SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CYCLOOXYGENASE 2 INHIBITOR; MALONALDEHYDE; MMP2 PROTEIN, RAT; PTGS2 PROTEIN, RAT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FIBRINOLYTIC THERAPY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; TIME; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCOGEN; LIVER; LIVER CIRRHOSIS; MALE; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77957124603     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02256.x     Document Type: Article

References (45)

1. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008, 28:1052-64.
2. Muriel P. Cytokines in liver diseases. Hepatotoxicity: from Genomics to in vitro and in vivo Models 2008, 371-89. Sahu S. In, ed, West Sussex, UK, John Wiley & Sons Ltd
3. Gressner AM, Weiskirchen R. Modern pathogenic concepts of liver fibrosis suggest stellate cells and TGF β as major players and therapeutics targets. J Cell Mol Med 2006, 10:76-99.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
5. Dieter P, Scheibe R, Jakobsson P. Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. Biochem Biophys Res Commun 2000, 276:488-92.
6. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA, McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 2004, 57:350-4.
7. Nanji AA, Miao L, Thomas P. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997, 112:943-51.
8. Kim SH, Chu HJ, Kang DH. NF-kappa B binding activity and cyclooxygenase-2 expression in persistent CCl(4)-treated rat liver injury. J Korean Med Sci 2002, 17:193-200.
9. Liu H, Peng Y, Liu F. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-β1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int 2007, 31:508-15.
10. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000, 57:2334-42.
11. Yamamoto H, Kondo M, Nakamori S. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 2003, 1252:556-71.
12. Reitman S, Frankel S. A colorimetric method for determination of serum oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957, 28:56-63.
13. Bergmeyer HU, Grabl M, Walter HE. Enzymes. Methods of Enzymatic Analysis 1983, 269-70. Bergmeyer J, Grabl M, In, eds, Weinheim, Verlag-Chemie
14. Glossman M, Neville DM. Glutamyl transferase in kidney brush border membranes. FEBS Lett 1972, 19:340-4.
15. Okawa H, Ohmishi N, Yagi K. Assay for lipid peroxides in animal tissues by the thiobarbituric acid reaction. Anal Biochem 1979, 95:351-8.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976, 72:248-54.
17. Prockop DJ, Underfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1960, 1:228-39.
18. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976, 74:214-26.
19. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with the anthrone reagent. Arch Biochem 1950, 25:191-200.
20. Garcia-Tovar CG, Perez A, Luna J. Biochemical and histochemical analysis of 71 kDa dystrophin isoform (Dp71f) in rat brain. Acta Histochem 2001, 103:209-24.
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980, 102:196-202.
22. Etique N, Grillier-Vuissoz I, Flament S. Ethanol stimulates the secretion of matrix metalloproteinases 2 and 9 in MCF-7 human breast cancer cells. Oncol Rep 2006, 15:603-8.
23. Parada B, Sereno J, Reis F. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther 2009, 8:7-14.
24. Petersen A, Carlsson T, Karlsson JO, Zetterberg M. Intracellular effects of NSAIDs/ASA in oxidatively stressed human lens epithelial cells in culture. Ophthalmic Res 2008, 40:77-85.
25. Miyajima A, Ito K, Asino T. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral obstruction? J Urol 2001, 166:1124-9.
26. Núñez O, Fernández-Martínez A, Majano PL. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53:1665-72.
27. Ramirez-Yañez GO, Hamlet S, Jonarta A, Seymour GJ, Symons AL. Prostaglandin E2 enhances transforming growth factor-beta 1 and TGF-beta receptors synthesis: an in vivo and in vitro study. Prostaglandins Leukot Essent Fatty Acids 2006, 74:183-92.
28. Püschel GP, Kirchner C, Schröder A, Jungermann K. Glycogenolytic and antiglycogenolytic prostaglandin E2 actions in rat hepatocytes are mediated via different signalling pathways. Eur J Biochem 1993, 218:1083-9.
29. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001, 21:351-72.
30. Roderfeld M, Geier A, Dietrich CG. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int 2006, 26:579-86.
31. Lichtinghagen R, Bahr MJ, Wehmeier M. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 2003, 105:373-82.
32. Reif S, Somech R, Brazovski E. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005, 71:124-30.
33. Zhou X, Hovell CJ, Pawley S. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2006, 26:380-1.
34. Han YP, Zhou L, Wang J. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004, 279:4820-8.
35. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007, 46:955-75.
36. Okazaki I, Watanabe T, Niioka M, Sugioka Y, Inagaki Y. Reversibility of liver fibrosis: role of matrix metalloproteinases. Fibrogenesis: Cellular and Molecular Basis 2005, 143-59. Razzaque MS, In, ed, Kluwer Academic Plenum Publishers
37. Yu J, Hui AY, Chu ES. The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. Liver Int 2009, 29:25-36.
38. Hui AY, Leung WK, Chan HL. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 2006, 26:125-36.
39. Kountouras J, Billing BH, Scheuer P. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984, 65:305-11.
40. Muriel P, Moreno MG, Hernández M del C, Chávez E, Alcantar LK. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin Pharmacol Toxicol 2005, 96:375-80.
41. Niederberger E, Tegeder I, Vetter G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB. FASEB J 2001, 15:1622-4.
42. Simon LS, Weaver AL, Graham DY. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282:1921-8.
43. Planagumà A, Clària J, Miquel R. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J 2005, 19:1120-2.
44. Denda A, Tang Q, Endoh T. Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, l-amino acid-defined diet in rats. Carcinogenesis 1994, 15:1279-83.
45. Paik YH, Kim JK, Lee JI. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 2009, 58:1517-27.